VII INT. CONG. THROMB. HAEM.

Poster Board 0320 FIBRINGEN SEATTLE: A HERITABLE DISFIBRINGEN WITH AN ISOLATED IMPAIRMENT IN FIBRINOPEPTIDE B RELEASE P5-045 H.E. Branson, I. Theodor, R. Baumgartner, G. Schmer, H. Pirkle, Departments of Pathology University of California Irvine, Irvine, California 92717, U.S.A. The slow clotting, asymptomatic, fibrinogen Seattle first described in a patient with tetralogy of Fallot has been traced through four generations as an autosomal dominant

prohibited with 70% penetrance. The dysfibrinogen was indistinguishable from normal fibrinogen by radial immunodiffusion and immunoelectrophoresis. Transamidation and plasmin digestion studies gave no evidence of abnormality. Thrombin and botroxobin monomer reprolymerization followed turbidometrically (A_{350}) disclosed a shorter lag phase, a more acute strictly maximal slope, and a lower maximal turbidity. Electron microscopy revealed that thrombin incubated fibrinogen Seattle more readily formed clots with aperiodic fibers than comparable controls. By amino acid analysis the final yield of fibrinopeptide B was <u>.</u>0 slightly more than half normal (54% at 2 hours with 2.5 NIH units/ml). The dysfibrin slightly more than half normal (54% at 2 hours with 2.5 NIH units/ml). The dysfibrin manifested evidence of retention of fibrinopeptide B as equal quantities of chains with Bß and β charge mobility were demonstrated on low pH (2.7) polyacrylamide electrophore-sis in 2M urea. A distinction is made between fibrinogen Seattle and fibrinogen Detroit both with disordered fibrinopeptide B release on the basis of the patterns of fibrino-peptide release, immunoelectrophoretic mobility, botroxobin monomer aggregation, chronopeptide release, immunoelectrophoretic mobility, botroxobin monomer aggregation, chronometric fibrinogen concentration, and clinical symptomatology. No other dysfibrinogens have been shown to manifest disordered release of fibrinopeptide B alone.

P5-046 0321 POLYMERISATION DEFECT OF FIBRINOGEN LONDON

D.A. Lane*, M. VanRoss, B. Cuddigan and V.V. Kakkar. Thrombosis Research Unit, King's College Hospital Medical School and the Brook General Hospital, London.

use only. Unauthorized In the present study further work has been carried out on fibrinogen that has been isolated from a patient with a coagulation defect tentatively designated fibrinogen Lonisolated from a patient with a coagulation defect tentatively designated fibrinogen Lon-don. The dysfibrinogenemia was characterised by normal polypeptide chains on SDS gel electrophoresis, normal release of fibrinopeptide A and a delayed polymerisation of fib-rin monomers. The polymerisation defect was pH and ionic strength dependent and partial-ly corrected by protamine sulphate and Ca⁺⁺ ions. Studies on the NH2 and COOH terminal ly corrected by protamine sulphate and Ca++ ions. Studies on the NH2 and COOH terminal polymerisation domains were carried out using insolubilised fibrin monomers prepared from Q patient and normal fibrinogen (Kudryk et al, Thromb.Res., 9,25, 1976). High MW fragment D, prepared by plasmin digestion of normal fibrinogen, bound to both normal and patient This document was downloaded fibrin monomer and was eluted with 8M urea indicating no gross malfunction of the NH2 terminal polymerisation domain. Also purified fibrinogens from normal and patient plasma bound to normal fibrin monomer sepharose, suggesting that the COOH terminal domain is capable of binding to the NH2 terminal domain of normal fibrin. These results suggest that the polymerisation defect of fibrinogen London is different in character to that of fibrinogen Detroit, where the NH2 terminal domain does not bind to the normal COOH terminal domain.

P5-047 0322 FIBRINGEN LOGROÑO. A NEW FIBRINGEN MOLECULAR VARIANT

J.Fernandez*, J.Lasierra, M.J.Narvaiza, E.Vilades, E.Palacios y E. Rocha. Haematology Services: Faculty of Medicine, University of Navarra, Pamplona and R.S. "Antonio Coello", Logroño, Spain.

We present a new molecular variant of fibrinogen. The majority of biological tests were normal except prolonged prothrombin and thrombin times, fibrinogen deficiency as quantified by a colourimetric method, and the polymerization of fibrin's monomers. Normal thrombin times were obtained by addition of normal plasma, bovine thrombin, ${\tt CaCl}_2,$ and by changes in pH and ionic strength.

The study of the purified fibrinogen showed normal fibrinopeptides' liberation and sialic acid and hexosamine levels. Fibrin stabilization, coagulability index = 64%, electrophoretic mobility, pI = 5.4 (N = 5.8), and $S_{20,w} = 10$ (N = 8.2), were abnor mal.

5